Часто задаваемые вопросы

What is Concizumab used for?

An antibody therapy designed to inhibit a protein called tissue factor pathway inhibitor (TFPI), which helps restore normal clotting in patients with hemophilia. It is being studied as a subcutaneous preventive treatment to reduce bleeding episodes.

How does Concizumab work?

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Is Concizumab an approved drug?

Yes, Concizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

• ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297730. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.